Liquid biopsy improves the diagnosis and treatment of medulloblastoma

Results from a proof-of-concept study led by Joan Seoane show the promise of cerebrospinal fluid as liquid biopsy for the more precise characterization and real time tracking of medulloblastoma.

Circulating tumor DNA from cerebrospinal fluid reveals genomic alterations during disease evolution -even prior to surgery- to more precisely guide treatment decision making.

Cerebrospinal fluid as liquid biopsy against medulloblastoma translates in less invasive sampling, better identification and characterization of disease relapse.